Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

1. Cefiderocol (Fetroja) - urinary tract infections

Cefiderocol (Fetroja) - urinary tract infections Drug Approval Package: FETROJA (cefiderocol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: FETROJA (cefiderocol) Company: Shionogi, Inc. Application Number: 209445Orig1s000 Approval Date: 11/14/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

2. Delafloxacin (Quofenix) - bacterial infections of the skin and underlying tissues

Delafloxacin (Quofenix) - bacterial infections of the skin and underlying tissues Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/572803/2019 EMEA/H/C/004860 Quofenix (...) (delafloxacin) An overview of Quofenix and why it is authorised in the EU What is Quofenix and what is it used for? Quofenix is an antibiotic used in adults to treat bacterial infections of the skin and underlying tissues (acute bacterial skin and skin structure infections) when other medicines are not suitable. It contains the active substance delafloxacin. How is Quofenix used? Quofenix is available as a powder to be made into a solution for infusion (300 mg) and as tablets (450 mg). Quofenix is given

2020 European Medicines Agency - EPARs

3. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study

Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study Overall Infection Risk in Rheumatoid Arthritis During Treatment With Abatacept, Rituximab and Tocilizumab; An Observational Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions 2019 Nov 25 [Online ahead of print] Overall Infection Risk in Rheumatoid Arthritis During Treatment With Abatacept, Rituximab and Tocilizumab; An Observational Cohort Study , , , , , , , Affiliations Expand Affiliations 1 DANBIO and Copenhagen

2020 EvidenceUpdates

4. Infants born to hepatitis B-infected mothers: immunoglobulin policy

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

2020 Public Health England

5. Wuhan novel coronavirus: infection prevention and control

Wuhan novel coronavirus: infection prevention and control Wuhan novel coronavirus: infection prevention and control - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Wuhan novel coronavirus: infection prevention and control Guidance on infection prevention and control for Wuhan (...) novel coronavirus. Published 10 January 2020 Last updated 15 January 2020 — From: Documents HTML Details This guidance outlines infection control for healthcare providers assessing possible cases of WN-CoV. It should be used in conjunction with local policies. In the absence of effective drugs or a vaccine, control of this virus relies on the prompt identification, appropriate risk assessment, management and isolation of possible and confirmed cases, and the investigation and follow up of close

2020 Public Health England

6. The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP

The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually (...) transmitted infection (STI) and considerations for their use of PrEP , , , , , , Questions What is the current evidence among women in high-income countries regarding HIV risk after acquiring a sexually transmitted infection (STI)? What does the evidence state regarding the use of pre-exposure prophylaxis (PrEP) to prevent HIV among women who have acquired an STI? Key take-home messages A recent study in the U.S. found that most women who were diagnosed with HIV did not have a reported STI in the past (1

2020 Ontario HIV Treatment Network

7. Managing common infections: guidance for primary care

Managing common infections: guidance for primary care Managing common infections: guidance for primary care - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Managing common infections: guidance for primary care Guidance for managing common infections, including upper and lower respiratory, and urinary tract infections. Published 5 August 2010 Last updated 2 August 2019 — From: and Documents https (...) of the guidance available for public consultation. 15 February 2017 Uploaded the new versions of documents. 23 May 2016 Published updated guidance and summary tables. 21 August 2015 Updated guidance documents published. 12 June 2015 Updated guidance following minor review in April 2015. 21 November 2014 Updates: dose of pivmecillinam corrected; wording within urinary tract infections (UTIs) in adults clarified to make it clear that nitrofurantoin is first line, and trimethoprim and pivmecillinam

2019 Public Health England

8. A systematic review on the use of muscle flaps for deep groin infection following vascular surgery

A systematic review on the use of muscle flaps for deep groin infection following vascular surgery The aim of this systematic review is to assess potential differences in effectiveness (graft loss and limb loss) between the sartorius muscle flap (SMF) and the rectus femoris muscle flap (RFF) coverage technique for deep groin wound infection following vascular surgery. Our hypothesis was that RFF reconstruction is more effective in groin coverage.The PubMed, Embase, and Medline databases were (...) systematically searched by two independent researchers for articles reporting effectiveness of both muscle flaps in the treatment of groin infections following vascular surgery. After quality assessment using the Newcastle-Ottawa Scale and Methodological Index for NOn-Randomized studies (MINOR) scores and data extraction, individual results of the included studies were reviewed. Weighted pooled outcome estimates were calculated.A total of 17 studies comprising 544 SMF reconstructions and 238 RFF

2019 EvidenceUpdates

9. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.We assembled a retrospective cohort of commercially insured adults in the USA diagnosed with PsO or PsA between 2015 and 2018. Exposure was dispensation (...) for IL-17 (ixekizumab or secukinumab), IL-12/23 (ustekinumab) or TNF (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab). The outcome was infection requiring hospitalisation after biologic initiation. Incidence rates (IRs) per 100 person-years were computed, and hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models, adjusted for inverse probability of treatment-weighted propensity scores.A total of 11 560 new

2019 EvidenceUpdates

10. O2 No Longer the Go2: A Systematic Review and Meta-Analysis Comparing the Effects of Giving Perioperative Oxygen Therapy of 30% FiO2 to 80% FiO2 on Surgical Site Infection and Mortality

O2 No Longer the Go2: A Systematic Review and Meta-Analysis Comparing the Effects of Giving Perioperative Oxygen Therapy of 30% FiO2 to 80% FiO2 on Surgical Site Infection and Mortality To determine the effects of perioperative high (80%) versus low (30%) fraction of inspired oxygen (FiO2) on surgical site infection (SSI) and mortality in adult surgical patients.The routine use of high fraction perioperative oxygen in patients is "standard of care" and recommended by the World Health

2019 EvidenceUpdates

11. Sexually Transmitted Infections in primary care consultations: development of an online tool to guide healthcare practitioners

Sexually Transmitted Infections in primary care consultations: development of an online tool to guide healthcare practitioners 2019 www.kce.fgov.be KCE REPORT 321 SEXUALLY TRANSMITTED INFECTIONS IN PRIMARY CARE CONSULTATIONS: DEVELOPMENT OF AN ONLINE TOOL TO GUIDE HEALTHCARE PRACTITIONERS 2019 www.kce.fgov.be KCE REPORT 321 GOOD CLINICAL PRACTICE SEXUALLY TRANSMITTED INFECTIONS IN PRIMARY CARE CONSULTATIONS: DEVELOPMENT OF AN ONLINE TOOL TO GUIDE HEALTHCARE PRACTITIONERS VICKY JESPERS, SABINE (...) STORDEUR, ANJA DESOMER, SAM CORDYN, TINE CORNELISSEN, TANIA CRUCITTI, CELINE DANHIER, IRITH DE BAETSELIER, ANNE-SOPHIE DE CANNIÈRE, WOUTER DHAEZE, ELS DUFRAIMONT, CHRIS KENYON, AGNES LIBOIS, SAPHIA MOKRANE, ELIZAVETA PADALKO, SANDRA VAN DEN EYNDE, WIM VANDEN BERGHE, THIERRY VAN DER SCHUEREN, NICOLE DEKKER COLOPHON Title: Sexually Transmitted Infections in primary care consultations: development of an online tool to guide healthcare practitioners Authors: Vicky Jespers (KCE), Sabine Stordeur (KCE), Anja

2019 Belgian Health Care Knowledge Centre

12. Cefepime dihydrochloride monohydrate (Renapime) - for the treatment of infections caused by bacteria that are cefepime-sensitive

Cefepime dihydrochloride monohydrate (Renapime) - for the treatment of infections caused by bacteria that are cefepime-sensitive Final Appraisal Recommendation Advice No: 1619 – November 2019 Cefepime dihydrochloride monohydrate (Renapime ® ) 1 g and 2 g powder for solution for injection or infusion Limited submission by Renascience Pharma Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4129 (...) Wales. Cefepime (Renapime ® ) is licensed for the treatment of infections caused by bacteria that are cefepime-sensitive: lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis; uncomplicated and complicated urinary tract infections, including pyelonephritis; skin and subcutaneous infections; intra-abdominal infections, including peritonitis

2019 All Wales Medicines Strategy Group

13. Synovasure alpha defensin tests for the diagnosis of hip and knee periprosthetic joint infection (PJI)

Synovasure alpha defensin tests for the diagnosis of hip and knee periprosthetic joint infection (PJI) SHTG Advice | 1 SHTG Advice Number 08 November 2019 In response to an enquiry from the Golden Jubilee National Hospital Synovasure® alpha defensin tests, as part of a bundle of tests, for the diagnosis of hip and knee periprosthetic joint infection (PJI) Advice for NHSScotland Laboratory-based Synovasure® test, used as part of a bundle of diagnostic tests It is not possible to establish (...) reliable estimates for the relative accuracy of the laboratory-based Synovasure® bundle of tests compared with standard diagnostic strategies used in NHSScotland. The evidence is insufficient in quality and quantity to draw conclusions on the routine use of Synovsaure® tests as part of a bundle of diagnostic tests for periprosthetic joint infection (PJI). Currently in Scotland, there is no clearly defined diagnostic strategy for PJI, with variation across hospitals and health boards. To establish

2019 SHTG Advice Statements

14. Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents

Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents Published 11 November 2019 1 Product update SMC2214 glecaprevir/pibrentasvir 100mg/40mg film-coated tablets (Maviret®) AbbVie Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated (...) submission glecaprevir/pibrentasvir (Maviret®) is accepted for use within NHSScotland. Indication under review: treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years. SMC has previously accepted glecaprevir/pibrentasvir for the treatment of chronic HCV infection in adults. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir/pibrentasvir. This advice is contingent upon the continuing

2019 Scottish Medicines Consortium

15. Hepatitis E: health protection response to reports of infection

Hepatitis E: health protection response to reports of infection Hepatitis E: health protection response to reports of infection - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote (...) in the General Election on 12 December. Guidance Hepatitis E: health protection response to reports of infection Guidance on low public health risk, surveillance process and follow up with contacts. Published 14 June 2012 Last updated 8 November 2019 — From: Documents Ref: PHE publications gateway number: GW-698 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you

2019 Public Health England

16. Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents

Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) infection in adolescents Final Appraisal Recommendation Advice No: 1319 – October 2019 Glecaprevir/pibrentasvir (Maviret ® ) 100 mg/40 mg film-coated tablets Limited submission by AbbVie Ltd. Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (...) as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to < 18 years. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group Final

2019 All Wales Medicines Strategy Group

17. Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection

Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection Prescrire IN ENGLISH - Spotlight ''Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection'', 1 November 2019 {1} {1} {1} | | > > > Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Dolutegravir (...) + rilpivirine (Juluca°) dual therapy in HIV infection FEATURED REVIEW First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options? Full review (3 pages) available for download by subscribers. Prescrire's rating NOTHING NEW In patients who have an undetectable viral load

2019 Prescrire

18. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} During the 12 weeks from new diagnosis, the addition of prophylactic levofloxacin to active myeloma treatment significantly reduced febrile episodes and deaths without increasing healthcare associated infections or carriage. {{author}} {{($index , , , , , , , , , , , , , , & . Mark T Drayson 1, * , Stella Bowcock 2 , Tim Planche 3 , Gulnaz Iqbal 4 , Guy Pratt 5 , Kwee Yong 6 , Jill Wood 4 , Kerry Raynes 4

2019 NIHR HTA programme

19. Leukomed Sorbact for preventing surgical site infection

Leukomed Sorbact for preventing surgical site infection Leukomed Sorbact for preventing surgical site infection Medtech innovation briefing Published: 14 November 2019 www.nice.org.uk/guidance/mib197 pathways Summary Summary The technology technology described in this briefing is Leukomed Sorbact. It is used for preventing surgical site infection (SSI) in closed surgical incisions with up to moderate exudate levels. The inno innovativ vative aspect e aspect is the hydrophobic dialkylcarbamoyl (...) ), also known as Sorbact surgical dressing, is a sterile, single-use, bacteria- binding, adhesive-bordered wound dressing. It is to prevent surgical site infection (SSI) in closed surgical wounds that have low to moderate levels of exudate. The dressing comprises an absorbent non-woven wound contact pad and an adhesive polyurethane film. The pad is made of white viscose polypropylene and polyester laminated to the proprietary dialkylcarbamoyl chloride (DACC)-coated Sorbact mesh. DACC's hydrophobicity

2019 National Institute for Health and Clinical Excellence - Advice

20. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation

Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can (...) at any time. Hide Search Register by 26 November to vote in the General Election on 12 December. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation Patients on nivolumab who present with diarrhoea or other symptoms of colitis, and those who do not respond to steroid treatment for immune-related colitis, should be investigated to exclude other causes, including infections such as cytomegalovirus (CMV). Published 18 October 2019 From: Therapeutic area

2019 MHRA Drug Safety Update